Physician profile
Anitha Koduru
NPI 1689803785
$6,305.98
in general payments reported to CMS, 2019-2025
33 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 91% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $680 · 2021: $886 · 2022: $1,004 · 2023: $1,045 · 2024: $1,114 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,540.09 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $746.01 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.87 | 2019-2024 | Jardiance |
| Abbott Laboratories | $525.48 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $501.61 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $462.28 | 2021-2025 | |
| Amgen INC. | $267.49 | 2019-2024 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $250.52 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $226.20 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $211.28 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.39 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $186.17 | 2020-2025 | |
| Exact Sciences Corporation | $98.41 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $83.40 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $48.49 | 2023 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.66 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $38.13 | 2023-2024 | Belsomra, Gardasil, Gardasil 9 |
| Amarin Pharma, INC. | $37.75 | 2020-2021 | |
| Janssen Biotech, INC. | $35.63 | 2023 | Tremfya |
| Sanofi Pasteur INC. | $25.14 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $24.51 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.01 | 2023 | |
| Xeris Pharmaceuticals, INC. | $20.87 | 2025 | Keveyis |
| Astellas Pharma US INC | $20.24 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $19.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.29 | 2022 | |
| Currax Pharmaceuticals LLC | $17.84 | 2023 | Contrave, Nexlizet, Nexletol |
| Biohaven Pharmaceuticals, INC. | $16.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.94 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.83 | 2020 | |
| Allergan, INC. | $13.40 | 2019 | |
| Eisai INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Koduru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.